D-Pharm Ltd (TASE: DPRM) has raised 12.8M NIS in aggregate. D-Pharm’s largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of 8.7M NIS and a third of the total funds raised were from the public. D-Pharm is a clinical-stage neuroscience company focused on the development of pioneering proprietary drugs for the treatment of CNS disorders. D-Pharm’s pipeline includes three products in the Phase 2 clinical stage of development; namely, THR-18 for safe thrombolysis, DP-b99 for acute pancreatitis, and DP-VPA for epilepsy, as well as a preclinical development pipeline for misfolded protein disorders such as Alzheimer’s disease, and other types of dementia. THR-18 aims to improve the safety profile of tPA and allow the only approved, desperately needed, therapy to reach the majority of stroke patients. Late last year, D-Pharm reported on a successful Phase 2a study of THR-18 in acute ischemic stroke (AIS) patients treated with the clot-busting thrombolytic drug tPA. In that study THR-18 significantly (p<0.05) decreased the number of patients with brain swelling (edema) and intracranial hemorrhage (ICH).